Trends Immunol. 2025 Jun 18:S1471-4906(25)00143-7. doi: 10.1016/j.it.2025.06.002. Online ahead of print.
ABSTRACT
Two recent studies, by Ely et al. and Apavaloaei et al., revealed that non-canonical antigens derived from unmutated, noncoding regions dominate the immunopeptidome of many cancers. Here, we discuss how this challenges conventional mutation-centric immunotherapies and highlight emerging strategies, including cryptic antigen- and TCR-targeted vaccines, as promising new clinically relevant paths in personalised and off-the-shelf cancer immunotherapy.
PMID:40537348 | DOI:10.1016/j.it.2025.06.002